Pro-gastrin-releasing peptide(31-98) as a tumour marker for small-cell lung cancer
Author Information
Author(s): M Takadal, Y Kusunoki, N Masuda, K Matui, T Yana, S Ushijima, K Iidal, K Tamura, T Komiya, I Kawasel, N Kikui, H Morino, M Fukuoka
Primary Institution: Osaka Prefectural Habikino Hospital
Hypothesis
Can ProGRP(31-98) serve as a more accurate tumour marker for small-cell lung cancer than neuron-specific enolase?
Conclusion
ProGRP(31-98) is a more effective tumour marker for diagnosing small-cell lung cancer compared to neuron-specific enolase.
Supporting Evidence
- ProGRP(31-98) showed a sensitivity of 72.3% in SCLC patients compared to 62.4% for NSE.
- ProGRP(31-98) levels were significantly higher in patients with extensive disease compared to those with limited disease.
- ProGRP(31-98) was significantly higher in patients with pure small-cell carcinoma than in those with mixed small-cell/large-cell carcinoma.
- Serial measurements showed a high correlation between decreased ProGRP(31-98) levels and clinical response to treatment.
Takeaway
Doctors are trying to find a better way to tell if someone has a type of lung cancer called small-cell lung cancer, and they think a special protein called ProGRP might help more than another protein called NSE.
Methodology
Serum levels of ProGRP(31-98) and NSE were measured in patients using a sandwich enzyme-linked immunosorbent assay.
Limitations
The study was retrospective and involved a limited number of patients for follow-up.
Participant Demographics
The study included 212 patients: 101 with small-cell lung cancer, 111 with non-small-cell lung cancer, and 114 with non-malignant lung diseases.
Statistical Information
P-Value
0.0001
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website